Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of VAS203 (Ronopterin) in Moderate and Severe Traumatic Brain Injury
2013-003368-29Phase 3Completed
- Sponsor
- Vasopharm
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in traumatic brain injury (TBI) comparing Ronopterin with Placebo (2 arms). Primary endpoint: Primary: 6‑month clinical outcome (eGOS-I). Started Mar 2016; status: completed.
02
Drugs
ronopterin
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on 2013-003368-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003368-29.